TYRA - NASDAQ
Tyra Biosciences, Inc.
$28.69
-5.6%Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
At a Glance
Live SnapshotTyra Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Tyra Biosciences, Inc. Cash Flow Statement
TYRA • NASDAQ
| Tyra Biosciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-119.9M | -86.5M | -69.1M | -55.3M | -26.3M | -9.3M | -4.1M | |
546K | 519K | 353K | 296K | 140K | 47K | 8K | |
28M | 22.8M | 0.0 | 10.6M | 2.9M | 439K | 0.0 | |
-2.1M | -5.9M | 12.3M | 3K | 3K | 17K | 934K | |
-1.6M | -729K | 6.4M | -5.8M | -481K | 1.1M | 505K | |
-95.1M | -69.8M | -50.1M | -50.3M | -23.7M | -7.8M | -2.6M | |
INVESTING ACTIVITIES | |||||||
-141K | -664K | -770K | -559K | -661K | -312K | -20K | |
(0.0) | (0.0) | (0.0) | (0.0) | (16K) | (0.0) | (0.0) | |
-101.3M | -263.6M | -143.8M | (0.0) | (0.0) | (0.0) | (0.0) | |
173.9M | 165.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 16.0 | 0.0 | 0.0 | |
(72.5M) | -98.4M | -144.6M | -559K | -645K | -312K | -20K | |
FINANCING ACTIVITIES | |||||||
8.1M | 199.6M | 1.5M | 632K | 181.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -9K | -17K | -8K | |
(0.0) | -420K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 2.6M | 0.0 | 0.0 | 514K | 140K | 165K | |
8.1M | 202.1M | 1.5M | 632K | 311.3M | 23.4M | 157K | |
CASH FLOW SUMMARY | |||||||
0.0 | 0.0 | 0.0 | -757K | 0.0 | 0.0 | 0.0 | |
-14.6M | 34M | -193.2M | -51M | 287M | 15.4M | -2.5M | |
93M | 59M | 251.2M | 302.2M | 15.5M | 108K | 2.6M | |
78.4M | 93M | 58M | 251.2M | 302.4M | 15.5M | 108K | |
-95.3M | -70.4M | -50.9M | -50.8M | -24.4M | -8.1M | -2.6M |
SEC Filings
TYRA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 17, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 01, 2025 | November 25, 2025 | 2025 |
Related Guides
Continue your TYRA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.